Eli Lilly And Co vs Nucor Corporation — how do they compare? Eli Lilly And Co trades at $1,221 (market cap $1.08T), while Nucor Corporation trades at $270.02 (market cap $61.93B). The key difference: Eli Lilly And Co is far larger — about 17.4× Nucor Corporation's market cap, and Nucor Corporation pays the higher dividend (0.82%). Which is the better fit depends on your goals.
| LLY | NUE | |
|---|---|---|
Market Cap | $1.08T | $61.93B |
Sector | Health | Basic Materials |
52-Week High | $1.24K | $274.74 |
52-Week Low | $639.43 | $131.78 |
Enterprise Value | $1.13T | $66.34B |
Dividend Yield | 0.57% | 0.82% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
Nucor (NUE) trades at $272.28, down 0.85% on the day, as the steel producer shows mixed technical signals with a bullish moving average trend but overbought RSI readings. Fundamentally, the company delivered strong Q2 2026 earnings beats with EPS of $4.84 versus $4.46 expected, while revenue trends show recovery from 2024 lows. Analyst sentiment remains positive with 59% buy ratings and a $279.63 consensus target, though recent tariff developments and cyclical steel demand create headwinds.
The outlook for NUE appears cautiously optimistic with improving earnings momentum and favorable analyst coverage, though investors face risks from steel price volatility and macroeconomic pressures. The stock's current valuation at 21.7x P/E appears reasonable given the earnings recovery trajectory, but requires sustained operational execution to justify further upside beyond current resistance levels near $275.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →